identification small molecule activators cryptochrome
impairment circadian clock associated numerous disorders including metabolic disease although small molecules modulate clock function might offer therapeutic approaches diseases compounds identified selectively target core clock proteins unbiased cell-based circadian phenotypic screen identified kl001 small molecule specifically interacts cryptochrome cry kl001 prevented ubiquitin-dependent degradation cry resulting lengthening circadian period combination mathematical modeling studies using kl001 revealed cry1 cry2 share similar functional role period regulation furthermore kl001-mediated cry stabilization inhibited glucagon-induced gluconeogenesis primary hepatocytes kl001 thus provides tool study regulation cry-dependent physiology aid development clock-based therapeutics diabetes
